Beyond Air Inc - Asset Resilience Ratio
Beyond Air Inc (XAIR) has an Asset Resilience Ratio of 13.85% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beyond Air Inc (XAIR) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2026)
This chart shows how Beyond Air Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Beyond Air Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Beyond Air Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Beyond Air Inc for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.90 Million | 13.85% |
| Total Liquid Assets | $4.90 Million | 13.85% |
Asset Resilience Insights
- Moderate Liquidity: Beyond Air Inc has 13.85% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beyond Air Inc Industry Peers by Asset Resilience Ratio
Compare Beyond Air Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
LENSAR Inc
NASDAQ:LNSR |
Medical Devices | 0.00% |
|
Lumos Diagnostics Holdings Ltd
AU:LDX |
Medical Devices | 14.18% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
DRTECH Corporation
KQ:214680 |
Medical Devices | 5.18% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 15.99% |
Annual Asset Resilience Ratio for Beyond Air Inc (2018–2026)
The table below shows the annual Asset Resilience Ratio data for Beyond Air Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 13.85% | $4.90 Million | $35.38 Million | +6.36pp |
| 2025-03-31 | 7.49% | $2.25 Million | $30.06 Million | -33.05pp |
| 2024-03-31 | 40.54% | $23.09 Million | $56.96 Million | +16.21pp |
| 2023-03-31 | 24.33% | $16.72 Million | $68.75 Million | -- |
| 2022-03-31 | 0.00% | $0.00 | $99.20 Million | -- |
| 2020-03-31 | 0.00% | $0.00 | $27.43 Million | -- |
| 2019-03-31 | 69.40% | $6.54 Million | $9.43 Million | -19.37pp |
| 2018-03-31 | 88.77% | $8.30 Million | $9.36 Million | -- |
About Beyond Air Inc
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and b… Read more